We recently conducted a genome-wide association study which identified a risk allele associated with decreased DOCK2 expression in patients with severe COVID-19, and we showed that blockade of DOCK2 activity with the small molecule inhibitor CPYPP increased the severity of pneumonia in a Syrian hamster model of SARS-CoV-2 infection (36). Here, DOCK2 is linked to COVID-19.